Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | 10% owner | July 31, 2025 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TriSalus Life Sciences, Inc.
Report date July 31, 2025 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,989,748 |
Reported balance
After 2025-07-31 transaction · row 1
1 source rowRow 1 · 2025-07-31 · Conversion · Acquired 759,000 · Balance 6,989,748 F1: Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-31 · Conversion · Disposed 230,000 · Balance 0 F2: Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share. F3: On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II.
F2: Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share.
F3: On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2025 Filed Apr 20, 2026 20:36 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | ConversionSeries A Convertible Preferred Stock · Derivative | 230,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001628280-26-026014 · wk-form4_1776717403.xml · derivative · entry 2 Frankenius Equity AB · CIK 0001988262 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 759,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share. F3 · shares: On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer. F3 · derivative.exercise_date: On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer. F3 · derivative.expiration_date: On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer. Read SEC document |
| July 31, 2025 Filed Apr 20, 2026 20:36 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | ConversionCommon Stock | 759,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-026014 · wk-form4_1776717403.xml · nonDerivative · entry 1 Frankenius Equity AB · CIK 0001988262 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,989,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:57 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | OtherSeries A Convertible Preferred Stock · Derivative | 205,853 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001415889-25-003620 · form4-02112025_100256.xml · derivative · entry 1 Frankenius Equity AB · CIK 0001988262 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,853 Underlying: Common Stock · 205,853 shares Expires not disclosed F1 · derivative.exercise_price: The conversion price (the "Conversion Price") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023. F2 · kind: Effective February 10, 2025, the Conversion Price of the 230,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock. F2 · shares: Effective February 10, 2025, the Conversion Price of the 230,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock. F3 · derivative.exercise_date: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 435,853 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election. F4 · derivative.expiration_date: All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027. F5 · derivative.underlying_shares: Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset. F3 · balance_after: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 435,853 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 23:03 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 62,972 | $3.97 | $249,998.84 |
DisclosureSEC source: 0001415889-24-029904 · form4-12192024_111252.xml · nonDerivative · entry 1 Frankenius Equity AB · CIK 0001988262 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,230,748 F1 · shares: The shares were issued in connection with the closing of the transaction contemplated by the Securities Purchase Agreement, entered into December 12, 2024, by and between the Issuer and Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.